GRI Bio (GRI) Revenue & Revenue Breakdown
GRI Bio Revenue Highlights
Latest Revenue (Y)
$21.77M
Latest Revenue (Q)
$4.91M
GRI Bio Revenue by Period
GRI Bio Revenue by Year
Date | Revenue | Change |
---|---|---|
2023-12-31 | $21.77M | 100.00% |
2022-12-31 | - | 100.00% |
2021-12-31 | - | -100.00% |
2020-12-31 | $100.00K | 100.00% |
2019-12-31 | - | 100.00% |
2018-12-31 | - | - |
GRI Bio generated $21.77M in revenue during NA 2023, up 100.00% compared to the previous quarter, and up Infinity% compared to the same period a year ago.
GRI Bio Revenue by Quarter
Date | Revenue | Change |
---|---|---|
2025-01-31 | $4.91M | 100.00% |
2024-10-31 | - | 100.00% |
2024-07-31 | - | 100.00% |
2024-04-30 | - | -100.00% |
2024-01-31 | $5.39M | 100.00% |
2023-09-30 | - | 100.00% |
2023-06-30 | - | 100.00% |
2023-03-31 | - | 100.00% |
2022-12-31 | - | 100.00% |
2022-09-30 | - | 100.00% |
2022-06-30 | - | 100.00% |
2022-03-31 | - | 100.00% |
2021-12-31 | - | 100.00% |
2021-09-30 | - | 100.00% |
2021-06-30 | - | 100.00% |
2021-03-31 | - | - |
GRI Bio generated $4.91M in revenue during Q4 2024, up 100.00% compared to the previous quarter, and up Infinity% compared to the same period a year ago.
GRI Bio Peer Comparison by Revenue
Ticker | Company | Last Year Revenue | Last Quarter Revenue |
---|---|---|---|
GLUE | Monte Rosa Therapeutics | $75.62M | $4.70M |
CNTB | Connect Biopharma | $26.03M | - |
GRI | GRI Bio | $21.77M | $4.91M |
CCCC | C4 Therapeutics | $20.76M | - |
GBIO | Generation Bio | $19.89M | $4.09M |
XLO | Xilio Therapeutics | $6.34M | $2.36M |
STTK | Shattuck Labs | $5.72M | $1.61M |
CUE | Cue Biopharma | $5.49M | $3.34M |
HCWB | HCW Biologics | $2.57M | $426.42K |
HOWL | Werewolf Therapeutics | $1.89M | $1.14M |
IKNA | Ikena Oncology | - | - |
ANEB | Anebulo Pharmaceuticals | - | - |
DSGN | Design Therapeutics | - | - |
EWTX | Edgewise Therapeutics | - | - |
PRLD | Prelude Therapeutics | - | - |
AVTE | Aerovate Therapeutics | - | - |
PASG | Passage Bio | - | - |
CELC | Celcuity | - | - |